"With the acquisition on INSM we added several other programs to our pipeline so at this point we are really building up a portfolio of products in the BioVentures area. I don't think it's quite ready to really kind of lay out a whole profile of what that pipeline looks like, but that will be a company we will be able to talk about in the future as it continues to develop." "And as announced the Merck BioVenture in the last year or so, we continue to do acquisitions with Insmed and relationships with Insmed & Avecia from a biological standpoint to build our infrastructure and manufacturing capabilities. So I think this will be an important part of our stratagy. It's not put on the back burner as some have suggested that would take place."